Intest Res > Volume 21(4); 2023 > Article |
|
Funding Source
The author received no financial support for the research, authorship, and/or publication of this article.
Baseline colonoscopy finding | 2020 USMSTF | 2020 BSG/ACPGBI/PHE | 2020 ESGE | 2021JGES | 2022 Korea |
---|---|---|---|---|---|
1-2 tubular adenomas < 10 mm | 7-10 yr | Return to screening | Return to screening | 3-5 yr | 5-10 yr |
3-4 tubular adenomas < 10 mm | 3-5 yr | Return to screening | Return to screening | 3 yr | 3-5 yr |
5-10 tubular adenomas < 10 mm | 3 yr | 3 yr | 3 yr | 3 yr | 3 yr |
Adenoma ≥ 10 mm | 3 yr | 3 yra | 3 yr | 1-3 yr | 3 yr |
Adenoma with high-grade dysplasia | 3 yr | 3 yra | 3 yr | 1-3 yr | 3 yr |
Adenoma with villous histology < 10 mm | 3 yr | Return to screening | Return to screening | 1-3 yr | 3 yr |
> 10 adenomas | 1 yr and consider genetic testing | Referred to BSG hereditary CRC guidelines (1-2 yr) | Genetic counseling | 1 yr | 1 yr and consider genetic testing |
Piecemeal resection of adenoma > 20 mm | 6 mo | 2-6 mob | 3-6 mo | 6 mo | 6 mo |
a The BSG/ACPGBI/PHE recommends surveillance after 3 years in the presence of 2 or more precancerous polyps.
USMSTF, U.S. Multi-Society Task Force; BSG, British Society of Gastroenterology; ACPGBI, Association of Coloproctology of Great Britain and Ireland; PHE, Public Health England; ESGE, European Society of Gastrointestinal Endoscopy; JGES, Japan Gastroenterological Endoscopy Society; CRC, colorectal cancer.
Baseline colonoscopy finding | 2020 USMSTF | 2020 BSG/ACPGBI/PHE | 2020 ESGE | 2021 JGESc | 2022 Korea |
---|---|---|---|---|---|
≤ 20 HPs in rectum or sigmoid colon < 10 mm or ≤ 20 HPs proximal to sigmoid colon < 10 mm | 10 yr | No recommendation | No recommendation | No recommendation | No recommendation |
HP > 10 mm | 3-5 yr | No recommendation | No recommendation | No recommendation | 3 yrd |
1-2 SSLs < 10 mm | 5-10 yr | Return to screening | Return to screening | No recommendation | 5-10 yr |
3-4 SSLs < 10 mm | 3-5 yr | Return to screening | Return to screening | No recommendation | 3-5 yr |
5-10 SSLs < 10 mm | 3 yr | 3 yr | No recommendation | No recommendation | 3 yr |
SSL ≥ 10 mm | 3 yr | 3 yra | 3 yr | No recommendation | 3 yr |
SSL with dysplasia | 3 yr | 3 yra | 3 yr | No recommendation | 3 yr |
TSA | 3 yr | 3 yra | 3 yr | No recommendation | 3 yr |
Piecemeal resection of SSL > 20 mm | 6 mo | 2-6 mob | 3-6 mo | No recommendation | 6 mo |
SPS | No recommendation | Referred to BSG hereditary CRC guidelines (1-2 yr) | No recommendation | 1 yr | No recommendation |
a The BSG/ACPGBI/PHE recommends surveillance after 3 years in the presence of 2 or more precancerous polyps.
c The JGES proposes surveillance intervals of 3-5 years for SSL without considering size and number.
d The Korean guidelines recommend a 3-year surveillance interval for serrated polyps ≥10 mm regardless of whether they are HPs or SSLs.
USMSTF, U.S. Multi-Society Task Force; BSG, British Society of Gastroenterology; ACPGBI, Association of Coloproctology of Great Britain and Ireland; PHE, Public Health England; ESGE, European Society of Gastrointestinal Endoscopy; JGES, Japan Gastroenterological Endoscopy Society; HP, hyperplastic polyp; SSL, sessile serrated lesion; TSA, traditional serrated adenoma; SPS, serrated polyposis syndrome; CRC, colorectal cancer.